Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Sofia – page 46

763 clinical trials in Sofia, Bulgaria across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sofia at a glance
763
clinical trials
  • Research sites17
Type of trial
Recruitment status
Quick filters

763 trials in Sofia

Open in trial search

Embolism

Not recruiting

Study on How REGN9933 and REGN7508 Help Prevent Blood Clots in Adults with a Peripherally Inserted Central Catheter (PICC)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Regn9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Poloxamer 407
  • Sponsor:Urogen Pharma Ltd.

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Study on the Long-Term Safety and Effectiveness of Ozanimod for Adults with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Alopecia areata

Not recruiting

Study of amlitelimab injection compared to placebo for adults with severe alopecia areata (hair loss)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Formycon AG

Study on Batoclimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Urinary tract infection+1

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Sofia

What the registry says about research in the country

01 Respiratory Research

Clinical studies focusing on respiratory infections and conditions, including trials for RSV, human metapneumovirus, and influenza vaccines in older adults. Research also includes investigations into asthma treatments and chronic rhinosinusitis management.

  • Respiratory Syncytial Virus (RSV)
  • Influenza Prevention
  • Chronic Rhinosinusitis
  • Asthma Management
02 Dermatological Studies

Comprehensive research into various skin conditions, evaluating new treatments for chronic urticaria, hidradenitis suppurativa, and different forms of psoriasis. These trials aim to improve patient outcomes through innovative therapeutic approaches.

  • Chronic Spontaneous Urticaria
  • Hidradenitis Suppurativa
  • Genital Psoriasis
  • Plaque Psoriasis
03 Autoimmune Disorders

Groundbreaking studies examining treatments for various autoimmune conditions, including multiple sclerosis, Sjögren's disease, and systemic sclerosis. Research focuses on developing targeted therapies to manage these chronic conditions.

  • Multiple Sclerosis
  • Sjögren's Disease
  • Systemic Sclerosis
  • Psoriatic Arthritis
04 Metabolic and Cardiovascular Research

Studies investigating treatments for metabolic disorders and heart conditions, including research on hypertriglyceridemia, obesity management, and heart failure prevention. Focus on both therapeutic interventions and preventive measures.

  • Hypertriglyceridemia
  • Obesity Management
  • Heart Failure Prevention
  • Cardiovascular Health
05 Oncology Research

Advanced clinical trials focusing on breast cancer treatments and blood disorders, particularly investigating new therapeutic approaches for advanced/metastatic breast cancer and myelodysplastic syndrome.

  • Advanced Breast Cancer
  • Myelodysplastic Syndrome
  • Targeted Therapies
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.